A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia

201743 citationsJournal Article

Authors

Good health and well-being

Published in: Leukemia Research

Volume 64, pp. 10-16

Field-Weighted Citation Impact: 3.01